Cardiac Tolerability of Concurrent Administration of Trastuzumab and Anthracycline-Based Regimen as Adjuvant Chemotherapy for Breast Cancer | Zendy

Naoki Watanabe | Zendy; Shoko Otsuka | Zendy; Yoko Sasaki | Zendy; Reiko Shimojima | Zendy; Yoji Wani | Zendy; Kaori Uchino | Zendy

Open Access

Cardiac Tolerability of Concurrent Administration of Trastuzumab and Anthracycline-Based Regimen as Adjuvant Chemotherapy for Breast Cancer

Author(s) -

Naoki Watanabe,

Shoko Otsuka,

Yoko Sasaki,

Reiko Shimojima,

Yoji Wani,

Kaori Uchino

Publication year - 2014

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000358754

Subject(s) - trastuzumab , medicine , epirubicin , anthracycline , cardiotoxicity , tolerability , ejection fraction , breast cancer , regimen , chemotherapy , oncology , cancer , heart failure , adverse effect

Retrospective analysis suggests that anthracycline-containing regimens may be superior to non-anthracycline-containing regimens in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, both trastuzumab and anthracycline have cardiotoxicity, and it remains unclear how to use trastuzumab in combination with an anthracycline to curtail their cardiotoxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research